Ozempic, tirzepatide and other GLP-1RAs - impact on ME/CFS

Dakota15

Thread 'LoCITT: Remote Long COVID Trial to Evaluate Repurposed Drug Across US'

Contagion Live: 'Remote Long COVID Trial to Evaluate Repurposed Drug Across US’

'Patients with Long COVID can now sign up to receive notifications about an upcoming fully remote clinical trial led by Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC). The trial will be conducted through CareEvolution’s MyDataHelps platform, enabling participants to enroll and take part from home.'

'The fully remote Long Covid Treatment Trial will enroll 1,000 U.S. participants to evaluate a repurposed drug for Long COVID treatment.’

'In an email interview with...
  • Like

A US remote trial investigating the impact of tirzepatide on Long Covid
 
MrMagoo said:
Very soon I’ll be evaluating the difference between Mounjaro and Wegovy / tirzepatide and ozempic
Click to expand...
Me too.
I haven't seen any studies looking at those who have transitioned and whether they can maintain good results on Wegovy after being on Mounjaro.

My GP has told me that around Xmas there should be more weight loss drugs being released. I know Eli Lilly have another drug in preparation but, when I last read about it, the Phase 3 trials hadn't been completed so I don't think that will reach the market for a while. I may be wrong.


edit: sorry I've mistaken the thread. I have had no increase in energy while on mounjaro: currently 11 months.
 
Binkie4 said:
Me too.
I haven't seen any studies looking at those who have transitioned and whether they can maintain good results on Wegovy after being on Mounjaro.

My GP has told me that around Xmas there should be more weight loss drugs being released. I know Eli Lilly have another drug in preparation but, when I last read about it, the Phase 3 trials hadn't been completed so I don't think that will reach the market for a while. I may be wrong.


edit: sorry I've mistaken the thread. I have had no increase in energy while on mounjaro: currently 11 months.
Click to expand...
I assume that there should be “some” continuing effect because both contain a GLP-1 receptor agonist.
Wegovy was always the slower losses/less losses overall when compared in trials though.
 
This may be what my GP was referring to. From the Independent-

"Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up to 20.1 percent of their body weight on eloralintide.

The once-weekly amylin analog injection could be an enticing alternative for people looking to reap the benefits of the most popular weight-loss drugs on the market without one of their least-favorable side effects.

Previous studies have shown that amylin analog drugs - which imitate the body’s natural production of the blood sugar-regulating hormone amylin - may lead to a lower loss of lean muscle mass than do GLP-1 drugs like Ozempic and Wegovy, among others.

The 11-month Phase 2 trial, which included 263 participants who are overweight or living with obesity, also showed improvements in blood pressure, blood sugar and in markers of inflammation.

"Obesity is a complex condition, and no single treatment works for everyone,” Dr. Liana Billings, Director of Clinical and Genetics Research in Diabetes and Cardiometabolic Disease at Endeavor Health, said in a statement."
 
Should people with ME be concerned about loss of muscle mass while taking these drugs? I noticed that as long as you didn’t have an underweight BMI, you could still qualify for the LoCITT trial. But presumably then a lot of people could qualify even if they don’t want to lose any weight or muscle…
 
This “paper” had been floating around my CFS groups, it’s mostly about MCAS, but lots of ppl using it to justify the use of GLP1 in ME/CFS since now in some circles ME/CFS is “comorbid” with MCAS. After reading these case reports I have to agree MCAS seems to encompass anything under the sun in these case studies. There doesn’t seem to be a real mechanism of action described in this paper. Just that GLP1 bring down inflammation in obesity and type 2 diabetes, mast cell has receptors for glp1, so it must bring down inflammation in MCAS. Please read all the highlighted case reports, there’s quite a few where the patient was obese so no wonder they felt better being on a GLP1 and losing weight…. The case reports seem to have any and every symptom logged as MCAS.

 
ChronicallyOverIt said:
This “paper” had been floating around my CFS groups, it’s mostly about MCAS, but lots of ppl using it to justify the use of GLP1 in ME/CFS since now in some circles ME/CFS is “comorbid” with MCAS. After reading these case reports I have to agree MCAS seems to encompass anything under the sun in these case studies. There doesn’t seem to be a real mechanism of action described in this paper. Just that GLP1 bring down inflammation in obesity and type 2 diabetes, mast cell has receptors for glp1, so it must bring down inflammation in MCAS. Please read all the highlighted case reports, there’s quite a few where the patient was obese so no wonder they felt better being on a GLP1 and losing weight…. The case reports seem to have any and every symptom logged as MCAS.

https://www.amjmedsci.org/article/S0002-9629(25)01106-1/fulltext
Click to expand...
We have a thread for the paper Utility of Glucagon-like peptide 1 receptor agonists in Mast Cell Activation Syndrome, 2025, Afrin, Blitsheyn et al
 
You must log in or register to reply here.
Back
Top Bottom